[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587466":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":66,"collaborators":68,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":18,"enrollmentInfo":88,"targetDuration":18,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Réunion","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaccinated group","EXPERIMENTAL","Patients who will be vaccinated with the IXCHIQ vaccine",[13],"Biological: IXCHIQ",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-vaccinated group","NO_INTERVENTION","Patient who will not be vaccinated",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BIOLOGICAL","IXCHIQ","Group of vaccinated arm will be with the IXCHIQ vaccine",[9],[26],{"name":27,"affiliation":28,"role":29},"Patrick GERARDIN, MD","CHU La Réunion","STUDY_DIRECTOR",[31,35],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},"CONTACT","(262) 2 62 35 9435","patrick.gerardin@chu-reunion.fr",{"name":36,"role":32,"phone":37,"phoneExt":18,"email":38},"Florence LEFEBVRE D'HELLENCOURT","+262 262 75 34 71","promotion.drci@chu-reunion.fr",[40],{"facility":28,"status":41,"city":42,"state":18,"zip":18,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Saint-Denis","France","FR",{"type":46,"coordinates":47},"Point",[48,49],2.35387,48.93564,{"lat":49,"lon":48},[52,53,56,58,60,62,64],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},{"name":54,"role":55,"phone":18,"phoneExt":18,"email":18},"Patrick Gérardin, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":57,"role":55,"phone":18,"phoneExt":18,"email":18},"Loic Raffray, MD, PhD",{"name":59,"role":55,"phone":18,"phoneExt":18,"email":18},"Ludovic Di Ascia, MD",{"name":61,"role":55,"phone":18,"phoneExt":18,"email":18},"Barbara Kuli, MD",{"name":63,"role":55,"phone":18,"phoneExt":18,"email":18},"Xavier Guillot, MD, PhD",{"name":65,"role":55,"phone":18,"phoneExt":18,"email":18},"Emilie Mosnier, MD, PhD",{"type":67,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[69,72,75,77],{"name":70,"class":71},"ANRS, Emerging Infectious Diseases","OTHER_GOV",{"name":73,"class":74},"Région La Réunion","UNKNOWN",{"name":76,"class":74},"ARS La Réunion",{"name":78,"class":71},"Direction Générale de l'Offre de Soins","100587466","phase-4-real-world-effectiveness-safety-and-immunogenicity-of-chikungunya-vaccination-in-populations-at-risk-of-severe-or-complicated-forms-prospective-study-in-la-runion-100587466",false,"NCT06928753","Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion","CHIK-RE-VAC","Inclusion Criteria:\n\n* Eligible for anti-chikungunya vaccination according to french Health Authority (HAS)\n* Beneficiary of social security coverage\n* Signature of informed consent form\n\nExclusion Criteria:\n\n* Pregnant women\n* Vaccine contraindication for patients undergoing medical treatment\n* Persons under guardianship, curatorship or safeguard of justice\n* Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration","ALL","18 Years",{"count":89,"type":90},1800,"ESTIMATED","INTERVENTIONAL",[93],"PHASE4","Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and\u002For chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.",[96],"Chikungunya Virus Infection",[98],"Prophylaxis, Safety, Efficacy, Vaccine effectiveness, Chikungunya","2025-07-28",{"date":101,"type":102},"2025-07-29","ACTUAL",{"date":104,"type":102},"2025-04-18",{"date":106,"type":90},"2026-10",{"name":5,"class":6},1]